Pfizer Inc (PFE-N) Stock Predictions - Stockchase
WATCH LIST
647
Pfizer Inc (PFE-N)

ON STOCKCHASE SINCE Oct 2000

biotechnology/pharmaceutical

Pfizer Inc

PFE-N

80 watching          
Join the Discussion

Pfizer Inc (PFE-N) SAVE Apr, 19, 2019, 9:26 am

39.38 0.5 (1.25%)

About Pfizer Inc (PFE-N)

Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. Pfizer is considered one of the world's largest pharmaceutical companies. More at Wikipedia

What the experts are saying about PFE-N



  • All
  • Filtered
Signal Opinion Expert
WEAK BUY
Pfizer Inc(PFE-N) 

March 25, 2019

Healthcare in general has outperformed in every bear market. A lot of it comes from large cap pharma companies. He prefers LLY-N. But there is no question that this one is interesting and has good management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Healthcare in general has outperformed in every bear market. A lot of it comes from large cap pharma companies. He prefers LLY-N. But there is no question that this one is interesting and has good management.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Fingold

VP and Por, Dynamic Funds...

Price Price
$41.890
Owned Owned
No

COMMENT
Pfizer Inc(PFE-N) 

March 21, 2019

It is a safe dividend play. He looks at total return so dividends are important but recommends you don’t get caught in a dividend trap where there is capital at risk. A lot of dividend payers have moved their valuations to historical high levels. You have to be careful.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
It is a safe dividend play. He looks at total return so dividends are important but recommends you don’t get caught in a dividend trap where there is capital at risk. A lot of dividend payers have moved their valuations to historical high levels. You have to be careful.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$42.350
Owned Owned
Unknown

TOP PICK
Pfizer Inc(PFE-N) 

March 11, 2019

He likes this group and PFE is one of the few that has tested support lines. This has big potential to return to the mid/high-$40s soon. He likes it here.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
He likes this group and PFE is one of the few that has tested support lines. This has big potential to return to the mid/high-$40s soon. He likes it here.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Elliott Fishman

Director o, Trading Services Gro...

Price Price
$41.500
Owned Owned
No

BUY
Pfizer Inc(PFE-N) 

February 22, 2019

Great long base from 2015-18. The greater the base, the better the case. It broke out in mid-2018 and pulled back a bit. It looks healthy though. The chart looks encouraging.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Great long base from 2015-18. The greater the base, the better the case. It broke out in mid-2018 and pulled back a bit. It looks healthy though. The chart looks encouraging.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Keith Richards

Portfolio , ValueTrend Wealth Ma...

Price Price
$42.960
Owned Owned
Unknown

TOP PICK
Pfizer Inc(PFE-N) 

February 8, 2019

He sees about 18% upside and likes the healthcare sector. Yield 3.43% (Analysts’ price target is $45.85)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
He sees about 18% upside and likes the healthcare sector. Yield 3.43% (Analysts’ price target is $45.85)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$42.095
Owned Owned
Yes

DON'T BUY
Pfizer Inc(PFE-N) 

February 6, 2019

Merck vs. Pfizer Two large pharma companies that are treading water. A lot of the drugs they develop are coming off patent. You must look at their pipelines, with Merck doing very well while Pfizer has some good franchises, like Lipitor. Merck likely has the better pipeline. Neither has enough revenue growth or cash flow to entice him to buy.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Merck vs. Pfizer Two large pharma companies that are treading water. A lot of the drugs they develop are coming off patent. You must look at their pipelines, with Merck doing very well while Pfizer has some good franchises, like Lipitor. Merck likely has the better pipeline. Neither has enough revenue growth or cash flow to entice him to buy.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$42.330
Owned Owned
No

PAST TOP PICK
Pfizer Inc(PFE-N) 

January 31, 2019

(A Top Pick Jan 10/18, Up 21%) This was the conservative pick. He thought it was oversold and it had a nice run back to where it is. He trimmed a little back and is not as positive on it now. They are going to pool their consumer product divisions with Glaxo. Probably 5-10% return this year.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Jan 10/18, Up 21%) This was the conservative pick. He thought it was oversold and it had a nice run back to where it is. He trimmed a little back and is not as positive on it now. They are going to pool their consumer product divisions with Glaxo. Probably 5-10% return this year.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Lauzon

Deputy Chi, Middlefield Capital ...

Price Price
$42.450
Owned Owned
Yes

DON'T BUY
Pfizer Inc(PFE-N) 

December 19, 2018

They make their money by constantly cost cutting. When their drugs go off-patent then they need to find another to replace it. It is a leaky-boat story. When you look at the cost multiples, which he thinks are expensive, he would pass on this. He would consider bio-pharma instead.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
They make their money by constantly cost cutting. When their drugs go off-patent then they need to find another to replace it. It is a leaky-boat story. When you look at the cost multiples, which he thinks are expensive, he would pass on this. He would consider bio-pharma instead.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$41.970
Owned Owned
No

BUY
Pfizer Inc(PFE-N) 

December 11, 2018

2019 outlook? The US healthcare sector has been very defensive in this market; they're not as off other sectors. The sector went sideways during the 2016 US election campaign. PFE has announced the price of 40-50 of their drugs will be raised. Plenty of runway in this company. But in 2019, if there's a market recovery, money will flow out of healthcare and back into tech. But you're good to own this.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
2019 outlook? The US healthcare sector has been very defensive in this market; they're not as off other sectors. The sector went sideways during the 2016 US election campaign. PFE has announced the price of 40-50 of their drugs will be raised. Plenty of runway in this company. But in 2019, if there's a market recovery, money will flow out of healthcare and back into tech. But you're good to own this.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Mike S. Newton,

Director &, Scotia Wealth Manage...

Price Price
$44.010
Owned Owned
Unknown

TOP PICK
Pfizer Inc(PFE-N) 

December 6, 2018

A defensive name. Revenues at $52 billion per year. ROE is going higher. Dividend yield is 3.0% and P/E is 15. Strong pipeline. (Analysts’ price target is $45.09)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A defensive name. Revenues at $52 billion per year. ROE is going higher. Dividend yield is 3.0% and P/E is 15. Strong pipeline. (Analysts’ price target is $45.09)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$44.980
Owned Owned
Unknown

HOLD
Pfizer Inc(PFE-N) 

December 3, 2018

Likes it. Diversified pharma. Good pipeline of assets that look robust. Trades at 15x earnings, which is reasonable. Slightly lower growth rate than peers but pays a good dividend. The chart looks fantastic and has benefited from the recent safety trade.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Likes it. Diversified pharma. Good pipeline of assets that look robust. Trades at 15x earnings, which is reasonable. Slightly lower growth rate than peers but pays a good dividend. The chart looks fantastic and has benefited from the recent safety trade.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$45.990
Owned Owned
Yes

PAST TOP PICK
Pfizer Inc(PFE-N) 

November 22, 2018

(A Top Pick Jan 10/18, Up 22%) Often last year's losers are this year's winners. This one he warmed up to when it had a good set-up. It is one of his main holdings in the healthcare space. They are becoming more innovative.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Jan 10/18, Up 22%) Often last year's losers are this year's winners. This one he warmed up to when it had a good set-up. It is one of his main holdings in the healthcare space. They are becoming more innovative.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Lauzon

Deputy Chi, Middlefield Capital ...

Price Price
$0.000
Owned Owned
Yes

DON'T BUY
Pfizer Inc(PFE-N) 

October 29, 2018

A very defensive stock with great products and brand, but little earnings growth, not enough for him. Pays a good dividend yield and the company won't go out of business. It will weather this downturn. He prefers Gilead.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A very defensive stock with great products and brand, but little earnings growth, not enough for him. Pays a good dividend yield and the company won't go out of business. It will weather this downturn. He prefers Gilead.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Don Lato

President, Padlock Investment M...

Price Price
$43.230
Owned Owned
No

HOLD
Pfizer Inc(PFE-N) 

August 23, 2018

Very much a value stock. Not a lot of growth. You can’t too far wrong at these levels. He likes a little more growth.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Very much a value stock. Not a lot of growth. You can’t too far wrong at these levels. He likes a little more growth.  

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Don Lato

President, Padlock Investment M...

Price Price
$42.200
Owned Owned
No

DON'T BUY
Pfizer Inc(PFE-N) 

August 7, 2018

Not a big owner of pharmaceuticals, because they’re under pricing pressure. Pfizer’s thinking of selling off consumer division. It’s OK, but the medical device sector’s doing better than pharma. Whole sector’s not performing well. Only pharma he owns is Novo Nordisk.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Not a big owner of pharmaceuticals, because they’re under pricing pressure. Pfizer’s thinking of selling off consumer division. It’s OK, but the medical device sector’s doing better than pharma. Whole sector’s not performing well. Only pharma he owns is Novo Nordisk.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$40.840
Owned Owned
No

Showing 1 to 15 of 647 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days